Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Neoplasms 6Solid Tumors 2Skin Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Melanoma 2Lung Neoplasms 2Leukemia, B-Cell 2Head and Neck Neoplasms 2Breast Neoplasms 2Vomiting 1Urinary Bladder Neoplasms 1Tracheal Diseases 1TP53 Y220C Mutation 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Salivary Gland Neoplasms 1Renal Insufficiency 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Nausea 1Myofibroma 1Mesothelioma 1

Interventions

pembrolizumab 8Pemetrexed 8capmatinib 7Carboplatin 7ceritinib 5Cisplatin 5Bevacizumab 4Docetaxel 3trametinib 2motexafin gadolinium 2aldesleukin 2Vinorelbine 2Paclitaxel 2Interleukin-2 2Gefitinib 2BID protein, human 2technetium 99m etarfolatide 1spartalizumab 1sintilimab 1satraplatin 1ribociclib 1picropodophyllin 1nazartinib 1naporafenib 1milademetan 1lazertinib 1fludarabine phosphate 1fludarabine 1farletuzumab 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma of Lung × Tablets × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡